Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
US Investment bank repeats 'buy' and US$8 price target on Tiziana Life Sciences after flurry of positive news
11:56am, Friday, 28'th May 2021
Investment bank B Riley has restated its 'buy' advice and US$8 price target for shares in Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) after a flurry of positive news. It said safety data on key
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
02:28pm, Thursday, 27'th May 2021
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per A
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
02:22pm, Thursday, 27'th May 2021
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per A
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
02:01pm, Thursday, 27'th May 2021
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per A
Tiziana Life's Foralumab Induces Immunomodulation, Anti-Inflammatory Effects In Early-Stage Study
06:37am, Wednesday, 26'th May 2021
Tiziana Life Sciences plc (NASDAQ: TLSA) has provided an update on further analysis of lymphocyte subsets from a Phase 1 study with nasally administered foralumab in healthy volunteers. Data showed s
Tiziana Life hails 'major accomplishment as nasally administered antibody shows potential to treat degenerative diseases such as MS
05:39am, Wednesday, 26'th May 2021
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered n
Tiziana Life PLC hails "major accomplishment" as nasally administered antibody shows potential to treat degenerative diseases such as MS
02:43am, Wednesday, 26'th May 2021
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered n
NEW YORK and LONDON, May 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeuti
TLSA Stock Price: Over 8% Increase Pre-Market Explanation
06:22am, Tuesday, 25'th May 2021
The stock price of Tiziana Life Sciences PLC (NASDAQ: TLSA) increased by over 8% pre-market. This is why it happened.
Tiziana Life Starts Testing Nasally Administered Foralumab in Multiple Sclerosis Patients
06:16am, Tuesday, 25'th May 2021
Under an individual patient expanded access program, Tiziana Life Sciences plc (NASDAQ: TLSA) has dosed the first patient with secondary progressive multiple sclerosis with nasally administered fo
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company's fully-human ant
NEW YORK and LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeuti
Tiziana Life Sciences confident of advancing drug development pipeline
09:15am, Tuesday, 18'th May 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it is confident that it is well positioned to advance its drug development programs "to their next respective value inflection points". Final re
Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
02:00am, Friday, 07'th May 2021
NEW YORK and LONDON, May 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and inf
Tiziana Life Sciences seeks clinical partner in Asia to progress work on liver cancer treatment
04:48am, Wednesday, 05'th May 2021
Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) announced an agreement with Takanawa Japan for a strategic business development plan to identify a clinical partner in Japan and other Asian countries
